Most-cited articles · 2023

The 50 most-cited articles in BMJ, 2023

Ranked by OpenAlex citation count on 29 October 2026, out of 1,645 eligible articles BMJ published in 2023. Ranks are frozen; this page will not change. Number one, with 521 citations: Advances in systemic therapies for triple negative breast cancer.

Cohort
1,645 articles
Listed
Top 50 (3.0%)
Open access
46 of 50
Snapshot
2026-10-29

Ask about these papers

Grounded in this list only, with sources.

3 of 3 free questions left today, no account needed
  1. 1
    top 0.1%

    Advances in systemic therapies for triple negative breast cancer

    Roberto Antonio Leon-Ferre, Matthew Philip Goetz

    521 citationsOpen accessdoi:10.1136/bmj-2022-071674OpenAlex

    Show abstract

    Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the highest rates of recurrence and mortality. The lack of expression of targetable proteins such as the estrogen receptor and absence of HER2 amplification have made relying on cytotoxic chemotherapy necessary for decades. In the operable setting, efforts to improve outcomes have focused on escalation of systemic therapy and a shift toward preoperative delivery followed by a response adapted approach to postoperative systemic therapy. An improved understanding of tumor biology has resulted in the identification of subsets of patients with specific molecular features, leading to testing and approval of multiple new targeted therapies for this disease. Furthermore, advances in drug development have led to the approval of antibody-drug conjugates that are redefining classification schemes for breast cancer. This review focuses on the modern management of TNBC, with particular focus on recent updates in the treatment of operable disease, and an overview of the most recent promising advances in the…

  2. 2
    top 0.2%

    Practical thematic analysis: a guide for multidisciplinary health services research teams engaging in qualitative analysis

    Catherine H. Saunders, Ailyn Sierpe, Christian von Plessen, Alice M. Kennedy, Laura C. Leviton and 10 more

    362 citationsOpen accessdoi:10.1136/bmj-2022-074256OpenAlex

    Show abstract

    Qualitative research methods explore and provide deep contextual understanding of real world issues, including people’s beliefs, perspectives, and experiences. Whether through analysis of interviews, focus groups, structured observation, or multimedia data, qualitative methods offer unique insights in applied health services research that other approaches cannot deliver. However, many clinicians and researchers hesitate to use these methods, or might not use them effectively, which can leave relevant areas of inquiry inadequately explored. Thematic analysis is one of the most common and flexible methods to examine qualitative data collected in health services research. This article offers practical thematic analysis as a step-by-step approach to qualitative analysis for health services researchers, with a focus on accessibility for patients, care partners, clinicians, and others new to thematic analysis. Along with detailed instructions covering three steps of reading, coding, and theming, the article includes additional novel and practical guidance on how to draft effective codes,…

  3. 3
    top 0.2%

    Dietary sugar consumption and health: umbrella review

    Yin Cheng Huang, Zeyu Chen, Bo Chen, Jinze Li, Xiang Lei Yuan and 13 more

    346 citationsOpen access (CC-BY)doi:10.1136/bmj-2022-071609OpenAlex

    Show abstract

    OBJECTIVE: To evaluate the quality of evidence, potential biases, and validity of all available studies on dietary sugar consumption and health outcomes. DESIGN: Umbrella review of existing meta-analyses. DATA SOURCES: PubMed, Embase, Web of Science, Cochrane Database of Systematic Reviews, and hand searching of reference lists. INCLUSION CRITERIA: Systematic reviews and meta-analyses of randomised controlled trials, cohort studies, case-control studies, or cross sectional studies that evaluated the effect of dietary sugar consumption on any health outcomes in humans free from acute or chronic diseases. RESULTS: The search identified 73 meta-analyses and 83 health outcomes from 8601 unique articles, including 74 unique outcomes in meta-analyses of observational studies and nine unique outcomes in meta-analyses of randomised controlled trials. Significant harmful associations between dietary sugar consumption and 18 endocrine/metabolic outcomes, 10 cardiovascular outcomes, seven cancer outcomes, and 10 other outcomes (neuropsychiatric, dental, hepatic, osteal, and allergic) were…

  4. 4
    top 0.3%

    Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study

    Barak Mizrahi, Tamar Sudry, Natalie Flaks‐Manov, Yoav Yehezkelli, Nir Kalkstein and 6 more

    335 citationsOpen access (CC-BY-NC)doi:10.1136/bmj-2022-072529OpenAlex

    Show abstract

    OBJECTIVES: To determine the clinical sequelae of long covid for a year after infection in patients with mild disease and to evaluate its association with age, sex, SARS-CoV-2 variants, and vaccination status. DESIGN: Retrospective nationwide cohort study. SETTING: Electronic medical records from an Israeli nationwide healthcare organisation. POPULATION: 1 913 234 Maccabi Healthcare Services members of all ages who did a polymerase chain reaction test for SARS-CoV-2 between 1 March 2020 and 1 October 2021. MAIN OUTCOME MEASURES: Risk of an evidence based list of 70 reported long covid outcomes in unvaccinated patients infected with SARS-CoV-2 matched to uninfected people, adjusted for age and sex and stratified by SARS-CoV-2 variants, and risk in patients with a breakthrough SARS-CoV-2 infection compared with unvaccinated infected controls. Risks were compared using hazard ratios and risk differences per 10 000 patients measured during the early (30-180 days) and late (180-360 days) time periods after infection. RESULTS: Covid-19 infection was significantly associated with increased…

  5. 5
    top 0.4%

    Prevalence, awareness, treatment, and control of hypertension in China, 2004-18: findings from six rounds of a national survey

    Mei Zhang, Yu Shi, Bin Zhou, Zhengjing Huang, Zhenping Zhao and 9 more

    306 citationsOpen access (CC-BY)doi:10.1136/bmj-2022-071952OpenAlex

    Show abstract

    Abstract Objective To assess the recent trends in prevalence and management of hypertension in China, nationally and by population subgroups. Design Six rounds of a national survey, China. Setting China Chronic Disease and Risk Factors Surveillance, 2004-18. Participants 642 523 community dwelling adults aged 18-69 years (30 501 in 2004, 47 353 in 2007, 90 491 in 2010, 156 836 in 2013, 162 293 in 2015, and 155 049 in 2018). Main outcome measures Hypertension was defined as a blood pressure of ≥140/90 mm Hg or taking antihypertensive drugs. The main outcome measures were hypertension prevalence and proportion of people with hypertension who were aware of their hypertension, who were treated for hypertension, and whose blood pressure was controlled below 140/90 mm Hg. Results The standardised prevalence of hypertension in adults aged 18-69 years in China increased from 20.8% (95% confidence interval 19.0% to 22.5%) in 2004 to 29.6% (27.8% to 31.3%) in 2010, then decreased to 24.7% (23.2% to 26.1%) in 2018. During 2010-18, the absolute annual decline in prevalence of hypertension among…

  6. 6
    top 0.4%

    Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

    Qingyang Shi, Kailei Nong, Per Olav Vandvik, Gordon Henry Guyatt, Oliver Schnell and 25 more

    293 citationsOpen access (CC-BY)doi:10.1136/bmj-2022-074068OpenAlex

    Show abstract

    OBJECTIVE: To compare the benefits and harms of drug treatments for adults with type 2 diabetes, adding non-steroidal mineralocorticoid receptor antagonists (including finerenone) and tirzepatide (a dual glucose dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist) to previously existing treatment options. DESIGN: Systematic review and network meta-analysis. DATA SOURCES: Ovid Medline, Embase, and Cochrane Central up to 14 October 2022. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Eligible randomised controlled trials compared drugs of interest in adults with type 2 diabetes. Eligible trials had a follow-up of 24 weeks or longer. Trials systematically comparing combinations of more than one drug treatment class with no drug, subgroup analyses of randomised controlled trials, and non-English language studies were deemed ineligible. Certainty of evidence was assessed following the GRADE (grading of recommendations, assessment, development and evaluation) approach. RESULTS: The analysis identified 816 trials with 471 038 patients, together…

  7. 7
    top 0.5%

    Air pollution deaths attributable to fossil fuels: observational and modelling study

    Jos Lelieveld, Andy Haines, Richard Thomas Burnett, Cathryn C. Tonne, Klaus Klingmüller and 2 more

    288 citationsOpen access (CC-BY-NC)doi:10.1136/bmj-2023-077784OpenAlex

    Show abstract

    OBJECTIVES: To estimate all cause and cause specific deaths that are attributable to fossil fuel related air pollution and to assess potential health benefits from policies that replace fossil fuels with clean, renewable energy sources. DESIGN: Observational and modelling study. METHODS: An updated atmospheric composition model, a newly developed relative risk model, and satellite based data were used to determine exposure to ambient air pollution, estimate all cause and disease specific mortality, and attribute them to emission categories. DATA SOURCES: Data from the global burden of disease 2019 study, observational fine particulate matter and population data from National Aeronautics and Space Administration (NASA) satellites, and atmospheric chemistry, aerosol, and relative risk modelling for 2019. RESULTS: Globally, all cause excess deaths due to fine particulate and ozone air pollution are estimated at 8.34 million (95% confidence interval 5.63 to 11.19) deaths per year. Most (52%) of the mortality burden is related to cardiometabolic conditions, particularly ischaemic heart…

  8. 8
    top 0.5%

    Comparison of mental health symptoms before and during the covid-19 pandemic: evidence from a systematic review and meta-analysis of 134 cohorts

    Ying Sun, Yin Wu, Suiqiong Fan, Tiffany Dal Santo, Letong Li and 21 more

    282 citationsOpen access (CC-BY-NC)doi:10.1136/bmj-2022-074224OpenAlex

    Show abstract

    OBJECTIVE: To synthesise results of mental health outcomes in cohorts before and during the covid-19 pandemic. DESIGN: Systematic review. DATA SOURCES: Medline, PsycINFO, CINAHL, Embase, Web of Science, China National Knowledge Infrastructure, Wanfang, medRxiv, and Open Science Framework Preprints. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Studies comparing general mental health, anxiety symptoms, or depression symptoms assessed from 1 January 2020 or later with outcomes collected from 1 January 2018 to 31 December 2019 in any population, and comprising ≥90% of the same participants before and during the covid-19 pandemic or using statistical methods to account for missing data. Restricted maximum likelihood random effects meta-analyses (worse covid-19 outcomes representing positive change) were performed. Risk of bias was assessed using an adapted Joanna Briggs Institute Checklist for Prevalence Studies. RESULTS: 0.11, 95% confidence interval -0.00 to 0.22) or anxiety symptoms (0.05, -0.04 to 0.13), but depression symptoms worsened minimally (0.12, 0.01 to 0.24). Among women or…

  9. 9
    top 0.6%

    CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials

    Daniela R. Junqueira, Liliane Zorzela, Su Golder, Yoon Kong Loke, Joel Joseph Gagnier and 11 more

    280 citationsOpen access (OTHER-OA)doi:10.1136/bmj-2022-073725OpenAlex

    Show abstract

    Randomised controlled trials remain the reference standard for healthcare research on effects of interventions, and the need to report both benefits and harms is essential. The Consolidated Standards of Reporting Trials (the main CONSORT) statement includes one item on reporting harms (ie, all important harms or unintended effects in each group). In 2004, the CONSORT group developed the CONSORT Harms extension; however, it has not been consistently applied and needs to be updated. Here, we describe CONSORT Harms 2022, which replaces the CONSORT Harms 2004 checklist, and shows how CONSORT Harms 2022 items could be incorporated into the main CONSORT checklist. Thirteen items from the main CONSORT were modified to improve harms reporting. Three new items were added. In this article, we describe CONSORT Harms 2022 and how it was integrated into the main CONSORT checklist, and elaborate on each item relevant to complete reporting of harms in randomised controlled trials. Until future work from the CONSORT group produces an updated checklist, authors, journal reviewers, and editors of…

  10. 10
    top 0.7%

    Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies

    Marco Solmi, Marco De Toffol, Jong Yeob Kim, Min Choi, Brendon Stubbs and 25 more

    273 citationsOpen access (CC-BY-NC)doi:10.1136/bmj-2022-072348OpenAlex

    Show abstract

    OBJECTIVE: To systematically assess credibility and certainty of associations between cannabis, cannabinoids, and cannabis based medicines and human health, from observational studies and randomised controlled trials (RCTs). DESIGN: Umbrella review. DATA SOURCES: PubMed, PsychInfo, Embase, up to 9 February 2022. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Systematic reviews with meta-analyses of observational studies and RCTs that have reported on the efficacy and safety of cannabis, cannabinoids, or cannabis based medicines were included. Credibility was graded according to convincing, highly suggestive, suggestive, weak, or not significant (observational evidence), and by GRADE (Grading of Recommendations, Assessment, Development and Evaluations) (RCTs). Quality was assessed with AMSTAR 2 (A Measurement Tool to Assess Systematic Reviews 2). Sensitivity analyses were conducted. RESULTS: 101 meta-analyses were included (observational=50, RCTs=51) (AMSTAR 2 high 33, moderate 31, low 32, or critically low 5). From RCTs supported by high to moderate certainty, cannabis based medicines…

  11. 11
    top 0.7%

    Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management

    Jason S. Knight, David Ware Branch, Thomas L. Ortel

    270 citationsdoi:10.1136/bmj-2021-069717OpenAlex

    Show abstract

    Antiphospholipid syndrome (APS) is a thrombo-inflammatory disease propelled by circulating autoantibodies that recognize cell surface phospholipids and phospholipid binding proteins. The result is an increased risk of thrombotic events, pregnancy morbidity, and various other autoimmune and inflammatory complications. Although antiphospholipid syndrome was first recognized in patients with lupus, the stand alone presentation of antiphospholipid syndrome is at least equally common. Overall, the diagnosis appears to affect at least one in 2000 people. Studies of antiphospholipid syndrome pathogenesis have long focused on logical candidates such as coagulation factors, endothelial cells, and platelets. Recent work has shed light on additional potential therapeutic targets within the innate immune system, including the complement system and neutrophil extracellular traps. Vitamin K antagonists remain the mainstay of treatment for most patients with thrombotic antiphospholipid syndrome and, based on current data, appear superior to the more targeted direct oral anticoagulants. The…

  12. 12
    top 0.8%

    Association between healthy lifestyle and memory decline in older adults: 10 year, population based, prospective cohort study

    Jianping Jia, Tan Zhao, Zhaojun Liu, Yumei Liang, Fangyu Li and 24 more

    251 citationsOpen access (CC-BY-NC)doi:10.1136/bmj-2022-072691OpenAlex

    Show abstract

    OBJECTIVE: To identify an optimal lifestyle profile to protect against memory loss in older individuals. DESIGN: Population based, prospective cohort study. SETTING: Participants from areas representative of the north, south, and west of China. PARTICIPANTS: Individuals aged 60 years or older who had normal cognition and underwent apolipoprotein E (APOE) genotyping at baseline in 2009. MAIN OUTCOME MEASURES: Participants were followed up until death, discontinuation, or 26 December 2019. Six healthy lifestyle factors were assessed: a healthy diet (adherence to the recommended intake of at least 7 of 12 eligible food items), regular physical exercise (≥150 min of moderate intensity or ≥75 min of vigorous intensity, per week), active social contact (≥twice per week), active cognitive activity (≥twice per week), never or previously smoked, and never drinking alcohol. Participants were categorised into the favourable group if they had four to six healthy lifestyle factors, into the average group for two to three factors, and into the unfavourable group for zero to one factor. Memory…

  13. 13
    top 0.8%

    Hypertensive disorders of pregnancy

    Pensée Wu, Marcus Green, Jenny Myers

    248 citationsdoi:10.1136/bmj-2022-071653OpenAlex

    Show abstract

    Hypertensive disorders of pregnancy (HDP) are one of the most commonly occurring complications of pregnancy and include chronic hypertension, gestational hypertension, and pre-eclampsia. New developments in early pregnancy screening to identify women at high risk for pre-eclampsia combined with targeted aspirin prophylaxis could greatly reduce the number of affected pregnancies. Furthermore, recent advances in the diagnosis of pre-eclampsia, such as placental growth factor based testing, have been shown to improve the identification of those pregnancies at highest risk of severe complications. Evidence from trials has refined the target blood pressure and timing of delivery to manage chronic hypertension and pre-eclampsia with non-severe features, respectively. Importantly, a wealth of epidemiological data now links HDP to future cardiovascular disease and diabetes decades after an affected pregnancy. This review discusses the current guidelines and research data on the prevention, diagnosis, management, and postnatal follow-up of HDP. It also discusses the gap in knowledge…

  14. 14
    top 0.9%

    Diagnosis and management of autoimmune hepatitis

    Luigi Muratori, Ansgar Wilhelm Lohse, Marco Lenzi

    236 citationsOpen accessdoi:10.1136/bmj-2022-070201OpenAlex

    Show abstract

    Autoimmune hepatitis is an inflammatory disease of the liver of unknown cause that may progress to liver cirrhosis and end stage liver failure if diagnosis is overlooked and treatment delayed. The clinical presentation is often that of acute hepatitis, sometimes very severe; less frequently, it can be insidious or completely asymptomatic. The disease can affect people of any age and is more common in women; its incidence and prevalence seem to be on the rise worldwide. An abnormal immune response targeting liver autoantigens and inducing persistent and self-perpetuating liver inflammation is the pathogenic mechanism of the disease. A specific set of autoantibodies, increased IgG concentrations, and histological demonstration of interface hepatitis and periportal necrosis are the diagnostic hallmarks of autoimmune hepatitis. Prompt response to treatment with corticosteroids and other immunomodulatory drugs is almost universal and supports the diagnosis. The aims of treatment are to induce and maintain long term remission of liver inflammation. Treatment can often even reverse liver…

  15. 15
    top 1%

    Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials

    Mina Nicole Händel, Isabel Cardoso, Cecilie von Bülow, Jeanett Friis Rohde, Anja Ussing and 17 more

    222 citationsOpen access (CC-BY-NC)doi:10.1136/bmj-2021-068033OpenAlex

    Show abstract

    Abstract Objective To review the comparative effectiveness of osteoporosis treatments, including the bone anabolic agents, abaloparatide and romosozumab, on reducing the risk of fractures in postmenopausal women, and to characterise the effect of antiosteoporosis drug treatments on the risk of fractures according to baseline risk factors. Design Systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. Data sources Medline, Embase, and Cochrane Library to identify randomised controlled trials published between 1 January 1996 and 24 November 2021 that examined the effect of bisphosphonates, denosumab, selective oestrogen receptor modulators, parathyroid hormone receptor agonists, and romosozumab compared with placebo or active comparator. Eligibility criteria for selecting studies Randomised controlled trials that included non-Asian postmenopausal women with no restriction on age, when interventions looked at bone quality in a broad perspective. The primary outcome was clinical fractures. Secondary outcomes were vertebral, non-vertebral,…

  16. 16
    top 1%

    Evaluating trends in private equity ownership and impacts on health outcomes, costs, and quality: systematic review

    Alexander Borsa, Geronimo Bejarano, Moriah Ellen, Joseph Dov Bruch

    206 citationsOpen access (CC-BY-NC)doi:10.1136/bmj-2023-075244OpenAlex

    Show abstract

    OBJECTIVE: To review the evidence on trends and impacts of private equity (PE) ownership of healthcare operators. DESIGN: Systematic review. DATA SOURCES: PubMed, Web of Science, Embase, Scopus, and SSRN. ELIGIBILITY CRITERIA FOR STUDY SELECTION: Empirical research studies of any design that evaluated PE owned healthcare operators. MAIN OUTCOME MEASURES: The main outcome measures were impact of PE ownership on health outcomes, costs to patients or payers, costs to operators, and quality. The secondary outcome measures were trends and prevalence of PE ownership of healthcare operators. DATA SYNTHESIS: Studies were classified as finding either beneficial, harmful, mixed, or neutral impacts of PE ownership on main outcome measures. Results across studies were narratively synthesized and reported. Risk of bias was evaluated using ROBINS-I (Risk Of Bias In Non-randomised Studies of Interventions). RESULTS: The electronic search identified 1778 studies, with 55 meeting the inclusion criteria. Studies spanned eight countries, with most (n=47) analyzing PE ownership of healthcare operators…

  17. 17
    top 1.1%

    Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study

    Tala Ballouz, Dominik Menges, Alexia Anagnostopoulos, Anja Domenghino, Hélène Eloise Aschmann and 3 more

    202 citationsOpen access (CC-BY-NC)doi:10.1136/bmj-2022-074425OpenAlex

    Show abstract

    OBJECTIVE: To evaluate longer term symptoms and health outcomes associated with post-covid-19 condition within a cohort of individuals with a SARS-CoV-2 infection. DESIGN: Population based, longitudinal cohort. SETTING: General population of canton of Zurich, Switzerland. PARTICIPANTS: 1106 adults with a confirmed SARS-CoV-2 infection who were not vaccinated before infection and 628 adults who did not have an infection. MAIN OUTCOME MEASURES: Trajectories of self-reported health status and covid-19 related symptoms between months six, 12, 18, and 24 after infection and excess risk of symptoms at six months after infection compared with individuals who had no infection. RESULTS: 22.9% (95% confidence interval 20.4% to 25.6%) of individuals infected with SARS-CoV-2 did not fully recover by six months. The proportion of individuals who had an infection who reported not having recovered decreased to 18.5% (16.2% to 21.1%) at 12 months and 17.2% (14.0% to 20.8%) at 24 months after infection. When assessing changes in self-reported health status, most participants had continued recovery…

  18. 18
    top 1.1%

    Transparent reporting of multivariable prediction models for individual prognosis or diagnosis: checklist for systematic reviews and meta-analyses (TRIPOD-SRMA)

    Kym I E Snell, Brooke Levis, Johanna AAG Damen, Paula Dhiman, Thomas P. A. Debray and 5 more

    201 citationsOpen access (CC-BY)doi:10.1136/bmj-2022-073538OpenAlex

    Show abstract

    Most clinical specialties have a plethora of studies that develop or validate one or more prediction models, for example, to inform diagnosis or prognosis. Having many prediction model studies in a particular clinical field motivates the need for systematic reviews and meta-analyses, to evaluate and summarise the overall evidence available from prediction model studies, in particular about the predictive performance of existing models. Such reviews are fast emerging, and should be reported completely, transparently, and accurately. To help ensure this type of reporting, this article describes a new reporting guideline for systematic reviews and meta-analyses of prediction model research.

  19. 19
    top 1.2%

    Ambient air pollution and clinical dementia: systematic review and meta-analysis

    Elissa H. Wilker, Marwa Osman, Marc G. Weisskopf

    186 citationsOpen access (CC-BY-NC)doi:10.1136/bmj-2022-071620OpenAlex

    Show abstract

    Abstract Objective To investigate the role of air pollutants in risk of dementia, considering differences by study factors that could influence findings. Design Systematic review and meta-analysis. Data sources EMBASE, PubMed, Web of Science, Psycinfo, and OVID Medline from database inception through July 2022. Eligibility criteria for selecting studies Studies that included adults (≥18 years), a longitudinal follow-up, considered US Environmental Protection Agency criteria air pollutants and proxies of traffic pollution, averaged exposure over a year or more, and reported associations between ambient pollutants and clinical dementia. Two authors independently extracted data using a predefined data extraction form and assessed risk of bias using the Risk of Bias In Non-randomised Studies of Exposures (ROBINS-E) tool. A meta-analysis with Knapp-Hartung standard errors was done when at least three studies for a given pollutant used comparable approaches. Results 2080 records identified 51 studies for inclusion. Most studies were at high risk of bias, although in many cases bias was…

  20. 20
    top 1.3%

    A guide and pragmatic considerations for applying GRADE to network meta-analysis

    Ariel Izcovich, Derek K. Chu, Reem A. Mustafa, Gordon Henry Guyatt, Romina Brignardello‐Petersen

    184 citationsOpen accessdoi:10.1136/bmj-2022-074495OpenAlex

    Show abstract

    Assessing the certainty of evidence from network meta-analyses using the GRADE (grading of recommendations, assessment, development, and evaluations) approach requires not only a thorough understanding of the methods but also substantial workload for raters. This article describes how implementing practical strategies (including rule setting and automation) can facilitate efficient application of the GRADE approach to rating certainty of evidence in network meta-analyses while maintaining rigor. This article describes a stepwise strategy for proceeding through the process, including assessment of the certainty of direct, indirect, and NMA estimates; developing directions for each step in the process; implementation of rules to improve robustness of information appraisal to reduce workload; and alternatives for automation of some of the required steps. The presented approach includes a detailed description of every step of the process supported by figures, tables, and real life examples. To facilitate implementation of this process, a spreadsheet that incorporates automation of…

  21. 21
    top 1.3%

    Interactive effects of ambient fine particulate matter and ozone on daily mortality in 372 cities: two stage time series analysis

    Cong Liu, Renjie Chen, Francesco Sera, Ana María Vicedo-Cabrera, Yuming Guo and 25 more

    174 citationsOpen access (CC-BY-NC)doi:10.1136/bmj-2023-075203OpenAlex

    Show abstract

    Abstract Objective To investigate potential interactive effects of fine particulate matter (PM 2.5 ) and ozone (O 3 ) on daily mortality at global level. Design Two stage time series analysis. Setting 372 cities across 19 countries and regions. Population Daily counts of deaths from all causes, cardiovascular disease, and respiratory disease. Main outcome measure Daily mortality data during 1994-2020. Stratified analyses by co-pollutant exposures and synergy index (>1 denotes the combined effect of pollutants is greater than individual effects) were applied to explore the interaction between PM 2.5 and O 3 in association with mortality. Results During the study period across the 372 cities, 19.3 million deaths were attributable to all causes, 5.3 million to cardiovascular disease, and 1.9 million to respiratory disease. The risk of total mortality for a 10 μg/m 3 increment in PM 2.5 (lag 0-1 days) ranged from 0.47% (95% confidence interval 0.26% to 0.67%) to 1.25% (1.02% to 1.48%) from the lowest to highest fourths of O 3 concentration; and for a 10 μg/m 3 increase in O 3 ranged…

  22. 22
    top 1.4%

    Management of perimenopausal and menopausal symptoms

    Erin R. Duralde, Talia Sobel, JoAnn E. Manson

    165 citationsOpen accessdoi:10.1136/bmj-2022-072612OpenAlex

    Show abstract

    Most women worldwide experience menopausal symptoms during the menopause transition or postmenopause. Vasomotor symptoms are most pronounced during the first four to seven years but can persist for more than a decade, and genitourinary symptoms tend to be progressive. Although the hallmark symptoms are hot flashes, night sweats, disrupted sleep, and genitourinary discomfort, other common symptoms and conditions are mood fluctuations, cognitive changes, low sexual desire, bone loss, increase in abdominal fat, and adverse changes in metabolic health. These symptoms and signs can occur in any combination or sequence, and the link to menopause may even be elusive. Estrogen based hormonal therapies are the most effective treatments for many of the symptoms and, in the absence of contraindications to treatment, have a generally favorable benefit:risk ratio for women below age 60 and within 10 years of the onset of menopause. Non-hormonal treatment options are also available. Although a symptom driven treatment approach with individualized decision making can improve health and quality of…

  23. 23
    top 1.4%

    Management of chronic pain associated with temporomandibular disorders: a clinical practice guideline

    Jason Walter Busse, Rodrigo Casassus, Alonso Carrasco‐Labra, Justin Durham, David Mock and 15 more

    163 citationsOpen accessdoi:10.1136/bmj-2023-076227OpenAlex

    Show abstract

    CLINICAL QUESTION: What is the comparative effectiveness of available therapies for chronic pain associated with temporomandibular disorders (TMD)? CURRENT PRACTICE: TMD are the second most common musculoskeletal chronic pain disorder after low back pain, affecting 6-9% of adults globally. TMD are associated with pain affecting the jaw and associated structures and may present with headaches, earache, clicking, popping, or crackling sounds in the temporomandibular joint, and impaired mandibular function. Current clinical practice guidelines are largely consensus-based and provide inconsistent recommendations. RECOMMENDATIONS: For patients living with chronic pain (≥3 months) associated with TMD, and compared with placebo or sham procedures, the guideline panel issued: (1) strong recommendations in favour of cognitive behavioural therapy (CBT) with or without biofeedback or relaxation therapy, therapist-assisted mobilisation, manual trigger point therapy, supervised postural exercise, supervised jaw exercise and stretching with or without manual trigger point therapy, and usual care…

  24. 24
    top 1.5%

    Long term outcomes of metabolic/bariatric surgery in adults

    Anita P. Courcoulas, Christopher Ryan Daigle, David E Arterburn

    162 citationsdoi:10.1136/bmj-2022-071027OpenAlex

    Show abstract

    The prevalence of obesity continues to rise around the world, driving up the need for effective and durable treatments. The field of metabolic/bariatric surgery has grown rapidly in the past 25 years, with observational studies and randomized controlled trials investigating a broad range of long term outcomes. Metabolic/bariatric surgery results in durable and significant weight loss and improvements in comorbid conditions, including type 2 diabetes. Observational studies show that metabolic/bariatric surgery is associated with a lower incidence of cardiovascular events, cancer, and death. Weight regain is a risk in a fraction of patients, and an association exists between metabolic/bariatric surgery and an increased risk of developing substance and alcohol use disorders, suicidal ideation/attempts, and accidental death. Patients need lifelong follow-up to help to reduce the risk of these complications and other nutritional deficiencies. Different surgical procedures have important differences in risks and benefits, and a clear need exists for more long term research about less…

  25. 25
    top 1.6%

    Autism intervention meta-analysis of early childhood studies (Project AIM): updated systematic review and secondary analysis

    Micheal P. Sandbank, Kristen Bottema‐Beutel, Shannon Crowley, Jacob I. Feldman, D. Jonah Barrett and 5 more

    161 citationsOpen access (CC-BY-NC)doi:10.1136/bmj-2023-076733OpenAlex

    Show abstract

    OBJECTIVE: To summarize the breadth and quality of evidence supporting commonly recommended early childhood autism interventions and their estimated effects on developmental outcomes. DESIGN: Updated systematic review and meta-analysis (autism intervention meta-analysis; Project AIM). DATA SOURCES: , and ClinicalTrials.gov. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Any controlled group study testing the effects of any non-pharmacological intervention on any outcome in young autistic children younger than 8 years. REVIEW METHODS: Newly identified studies were integrated into the previous dataset and were coded for participant, intervention, and outcome characteristics. Interventions were categorized by type of approach (such as behavioral, developmental, naturalistic developmental behavioral intervention, and technology based), and outcomes were categorized by domain (such as social communication, adaptive behavior, play, and language). Risks of bias were evaluated following guidance from Cochrane. Effects were estimated for all intervention and outcome types with sufficient…

  26. 26
    top 1.6%

    Ultra-processed foods and cardiometabolic health: public health policies to reduce consumption cannot wait

    Mathilde Touvier, Maria Laura da Costa Louzada, Dariush Mozaffarian, Phillip Baker, Filippa Juul and 1 more

    159 citationsOpen access (CC-BY-NC)doi:10.1136/bmj-2023-075294OpenAlex

    Show abstract

    Incomplete understanding of the multiple mechanisms underlying the link between ultra-processed foods and cardiometabolic health should not be an excuse for inaction argue Mathilde Touvier and colleagues

  27. 27
    top 1.7%

    Ionising radiation and cardiovascular disease: systematic review and meta-analysis

    Mark P. Little, Tamara V. Azizova, David B. Richardson, Soile Tapio, Marie‐Odile Bernier and 11 more

    157 citationsOpen access (CC-BY-NC)doi:10.1136/bmj-2022-072924OpenAlex

    Show abstract

    OBJECTIVE: To systematically review and perform a meta-analysis of radiation associated risks of cardiovascular disease in all groups exposed to radiation with individual radiation dose estimates. DESIGN: Systematic review and meta-analysis. MAIN OUTCOME MEASURES: Excess relative risk per unit dose (Gy), estimated by restricted maximum likelihood methods. DATA SOURCES: PubMed and Medline, Embase, Scopus, Web of Science Core collection databases. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Databases were searched on 6 October 2022, with no limits on date of publication or language. Animal studies and studies without an abstract were excluded. RESULTS: The meta-analysis yielded 93 relevant studies. Relative risk per Gy increased for all cardiovascular disease (excess relative risk per Gy of 0.11 (95% confidence interval 0.08 to 0.14)) and for the four major subtypes of cardiovascular disease (ischaemic heart disease, other heart disease, cerebrovascular disease, all other cardiovascular disease). However, interstudy heterogeneity was noted (P<0.05 for all endpoints except for other…

  28. 28
    top 1.8%

    Social media use and health risk behaviours in young people: systematic review and meta-analysis

    Amrit Kaur Purba, RM Thomson, Paul Henery, Anna Pearce, Marion Henderson and 1 more

    156 citationsOpen access (CC-BY)doi:10.1136/bmj-2022-073552OpenAlex

    Show abstract

    Abstract Objectives To examine the association between social media use and health risk behaviours in adolescents (defined as those 10-19 years). Design Systematic review and meta-analysis. Data sources EMBASE, Medline, APA PsycINFO, SocINDEX, CINAHL, SSRN, SocArXic, PsyArXiv, medRxiv, and Google Scholar (1 January 1997 to 6 June 2022). Methods Health risk behaviours were defined as use of alcohol, drugs, tobacco, electronic nicotine delivery systems, unhealthy dietary behaviour, inadequate physical activity, gambling, and anti-social, sexual risk, and multiple risk behaviours. Included studies reported a social media variable (ie, time spent, frequency of use, exposure to health risk behaviour content, or other social media activities) and one or more relevant outcomes. Screening and risk of bias assessments were completed independently by two reviewers. Synthesis without meta-analysis based on effect direction and random-effects meta-analyses was used. Effect modification was explored using meta-regression and stratification. Certainty of evidence was assessed using GRADE (Grading…

  29. 29
    top 1.8%

    Diagnosis and management of bipolar disorders

    Fernando S. Goes

    149 citationsOpen accessdoi:10.1136/bmj-2022-073591OpenAlex

    Show abstract

    Bipolar disorders (BDs) are recurrent and sometimes chronic disorders of mood that affect around 2% of the world's population and encompass a spectrum between severe elevated and excitable mood states (mania) to the dysphoria, low energy, and despondency of depressive episodes. The illness commonly starts in young adults and is a leading cause of disability and premature mortality. The clinical manifestations of bipolar disorder can be markedly varied between and within individuals across their lifespan. Early diagnosis is challenging and misdiagnoses are frequent, potentially resulting in missed early intervention and increasing the risk of iatrogenic harm. Over 15 approved treatments exist for the various phases of bipolar disorder, but outcomes are often suboptimal owing to insufficient efficacy, side effects, or lack of availability. Lithium, the first approved treatment for bipolar disorder, continues to be the most effective drug overall, although full remission is only seen in a subset of patients. Newer atypical antipsychotics are increasingly being found to be effective in…

  30. 30
    top 1.9%

    Comparison of seven popular structured dietary programmes and risk of mortality and major cardiovascular events in patients at increased cardiovascular risk: systematic review and network meta-analysis

    Giorgio Karam, Arnav Agarwal, Behnam Sadeghirad, Matthew Jalink, Christine L. Hitchcock and 12 more

    148 citationsOpen access (CC-BY-NC)doi:10.1136/bmj-2022-072003OpenAlex

    Show abstract

    OBJECTIVE: To determine the relative efficacy of structured named diet and health behaviour programmes (dietary programmes) for prevention of mortality and major cardiovascular events in patients at increased risk of cardiovascular disease. DESIGN: Systematic review and network meta-analysis of randomised controlled trials. DATA SOURCES: AMED (Allied and Complementary Medicine Database), CENTRAL (Cochrane Central Register of Controlled Trials), Embase, Medline, CINAHL (Cumulative Index to Nursing and Allied Health Literature), and ClinicalTrials.gov were searched up to September 2021. STUDY SELECTION: Randomised trials of patients at increased risk of cardiovascular disease that compared dietary programmes with minimal intervention (eg, healthy diet brochure) or alternative programmes with at least nine months of follow-up and reporting on mortality or major cardiovascular events (such as stroke or non-fatal myocardial infarction). In addition to dietary intervention, dietary programmes could also include exercise, behavioural support, and other secondary interventions such as drug…

  31. 31
    top 1.9%

    Breast cancer mortality in 500 000 women with early invasive breast cancer diagnosed in England, 1993-2015: population based observational cohort study

    Carolyn Taylor, Paul McGale, Jake Probert, John Broggio, Jackie Charman and 6 more

    137 citationsOpen access (CC-BY)doi:10.1136/bmj-2022-074684OpenAlex

    Show abstract

    OBJECTIVES: To describe long term breast cancer mortality among women with a diagnosis of breast cancer in the past and estimate absolute breast cancer mortality risks for groups of patients with a recent diagnosis. DESIGN: Population based observational cohort study. SETTING: Routinely collected data from the National Cancer Registration and Analysis Service. PARTICIPANTS: All 512 447 women registered with early invasive breast cancer (involving only breast and possibly axillary nodes) in England during January 1993 to December 2015, with follow-up to December 2020. MAIN OUTCOME MEASURES: Annual breast cancer mortality rates and cumulative risks by time since diagnosis, calendar period of diagnosis, and nine characteristics of patients and tumours. RESULTS: For women with a diagnosis made within each of the calendar periods 1993-99, 2000-04, 2005-09, and 2010-15, the crude annual breast cancer mortality rate was highest during the five years after diagnosis and then declined. For any given time since diagnosis, crude annual breast cancer mortality rates and risks decreased with…

  32. 32
    top 2%

    Guidelines should consider clinicians’ time needed to treat

    Minna Johansson, Gordon Henry Guyatt, Víctor M. Montori

    136 citationsdoi:10.1136/bmj-2022-072953OpenAlex

    Show abstract

    Minna Johansson, Gordon Guyatt, and Victor Montori argue that assessing the implementation time of guidelines would help make best use of clinical resources

  33. 33
    top 2.1%

    Suicide in young people: screening, risk assessment, and intervention

    Jennifer L. Hughes, Lisa M. Horowitz, J.P. Ackerman, Molly C. Adrian, John V. Campo and 1 more

    135 citationsOpen accessdoi:10.1136/bmj-2022-070630OpenAlex

    Show abstract

    Suicide is the fourth leading cause of death among young people worldwide and the third leading cause of death among those in the US. This review outlines the epidemiology of suicide and suicidal behavior in young people. It discusses intersectionality as an emerging framework to guide research on prevention of suicide in young people and highlights several clinical and community settings that are prime targets for implementation of effective treatment programs and interventions aimed at rapidly reducing the suicide rate in young people. It provides an overview of current approaches to screening and assessment of suicide risk in young people and the commonly used screening tools and assessment measures. It discusses universal, selective, and indicated evidence based suicide focused interventions and highlights components of psychosocial interventions with the strongest evidence for reducing risk. Finally, the review discusses suicide prevention strategies in community settings and considers future research directions and questions challenging the field.

  34. 34
    top 2.1%

    ROB-ME: a tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis

    Matthew James Page, Jonathan A C Sterne, Isabelle Boutron, Asbjørn Hróbjartsson, Jamie J Kirkham and 14 more

    134 citationsOpen accessdoi:10.1136/bmj-2023-076754OpenAlex

    Show abstract

    Various methods are available to help users assess whether selective non-publication of studies or selective non-reporting of study results has occurred, but not its impact on a meta-analysis. This limitation of existing methods leaves users to decide their own approach for judging the risk of bias in a meta-analysis result. In this paper, Page and colleagues describe the ROB-ME (risk of bias due to missing evidence) tool, a structured approach for assessing the risk of bias that arises when entire studies, or particular results within studies, are missing from a meta-analysis because of the P value, magnitude, or direction of the study results. The tool is anticipated to help authors and users of systematic reviews identify meta-analyses at high risk of bias and interpret results appropriately.

  35. 35
    top 2.2%

    Cancer mortality after low dose exposure to ionising radiation in workers in France, the United Kingdom, and the United States (INWORKS): cohort study

    David B. Richardson, Klervi Leuraud, Dominique Laurier, Michael Gillies, Richard Haylock and 7 more

    128 citationsOpen access (CC-BY-NC)doi:10.1136/bmj-2022-074520OpenAlex

    Show abstract

    OBJECTIVE: To evaluate the effect of protracted low dose, low dose rate exposure to ionising radiation on the risk of cancer. DESIGN: Multinational cohort study. SETTING: Cohorts of workers in the nuclear industry in France, the UK, and the US included in a major update to the International Nuclear Workers Study (INWORKS). PARTICIPANTS: 309 932 workers with individual monitoring data for external exposure to ionising radiation and a total follow-up of 10.7 million person years. MAIN OUTCOME MEASURES: Estimates of excess relative rate per gray (Gy) of radiation dose for mortality from cancer. RESULTS: The study included 103 553 deaths, of which 28 089 were due to solid cancers. The estimated rate of mortality due to solid cancer increased with cumulative dose by 52% (90% confidence interval 27% to 77%) per Gy, lagged by 10 years. Restricting the analysis to the low cumulative dose range (0-100 mGy) approximately doubled the estimate of association (and increased the width of its confidence interval), as did restricting the analysis to workers hired in the more recent years of…

  36. 36
    top 2.2%

    Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial

    Bridie S. Thompson, Mary A. Waterhouse, Dallas R. English, Donald S.A. McLeod, Bruce Konrad Armstrong and 11 more

    126 citationsOpen access (CC-BY-NC)doi:10.1136/bmj-2023-075230OpenAlex

    Show abstract

    OBJECTIVE: To investigate whether supplementing older adults with monthly doses of vitamin D alters the incidence of major cardiovascular events. DESIGN: Randomised, double blind, placebo controlled trial of monthly vitamin D (the D-Health Trial). Computer generated permuted block randomisation was used to allocate treatments. SETTING: Australia from 2014 to 2020. PARTICIPANTS: 21 315 participants aged 60-84 years at enrolment. Exclusion criteria were self-reported hypercalcaemia, hyperparathyroidism, kidney stones, osteomalacia, sarcoidosis, taking >500 IU/day supplemental vitamin D, or unable to give consent because of language or cognitive impairment. INTERVENTION: (n=10 662) or placebo (n=10 653) taken orally for up to five years. 16 882 participants completed the intervention period: placebo 8270 (77.6%); vitamin D 8552 (80.2%). MAIN OUTCOME MEASURES: The main outcome for this analysis was the occurrence of a major cardiovascular event, including myocardial infarction, stroke, and coronary revascularisation, determined through linkage with administrative datasets. Each event…

  37. 37
    top 2.3%

    Advances in the management of systemic lupus erythematosus

    Eric Francis Morand, Ruth Fernandez‐Ruiz, Ashira Blazer, Timothy B. Niewold

    117 citationsOpen accessdoi:10.1136/bmj-2022-073980OpenAlex

    Show abstract

    Systemic lupus erythematosus (SLE) is a severe multisystem autoimmune disease that can cause injury in almost every body system. While considered a classic example of autoimmunity, it is still relatively poorly understood. Treatment with immunosuppressive agents is challenging, as many agents are relatively non-specific, and the underlying disease is characterized by unpredictable flares and remissions. This State of The Art Review provides a comprehensive current summary of systemic lupus erythematosus based on recent literature. In basic and translational science, this summary includes the current state of genetics, epigenetics, differences by ancestry, and updates about the molecular and immunological pathogenesis of systemic lupus erythematosus. In clinical science, the summary includes updates in diagnosis and classification, clinical features and subphenotypes, and current guidelines and strategies for treatment. The paper also provides a comprehensive review of the large number of recent clinical trials in systemic lupus erythematosus. Current knowns and unknowns are…

  38. 38
    top 2.4%

    Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management

    Ben Fleming, Paul Edison, Laura M. Kenny

    115 citationsOpen accessdoi:10.1136/bmj-2022-071726OpenAlex

    Show abstract

    Cognitive impairment is a debilitating side effect experienced by patients with cancer treated with systemically administered anticancer therapies. With around 19.3 million new cases of cancer worldwide in 2020 and the five year survival rate growing from 50% in 1970 to 67% in 2013, an urgent need exists to understand enduring side effects with severe implications for quality of life. Whereas cognitive impairment associated with chemotherapy is recognized in patients with breast cancer, researchers have started to identify cognitive impairment associated with other treatments such as immune, endocrine, and targeted therapies only recently. The underlying mechanisms are diverse and therapy specific, so further evaluation is needed to develop effective therapeutic interventions. Drug and non-drug management strategies are emerging that target mechanistic pathways or the cognitive deficits themselves, but they need to be rigorously evaluated. Clinically, consistent use of objective diagnostic tools is necessary for accurate diagnosis and clinical characterization of cognitive…

  39. 39
    top 2.4%

    Social, clinical, and policy implications of ultra-processed food addiction

    Ashley Nicole Gearhardt, Nassib Bezerra Bueno, Alexandra G. DiFeliceantonio, Christina A. Roberto, Susana Jiménez‐Múrcia and 1 more

    113 citationsOpen access (CC-BY-NC)doi:10.1136/bmj-2023-075354OpenAlex

    Show abstract

    Conceptualising ultra-processed foods high in carbohydrates and fats as addictive substances can contribute to efforts to improve health, argue Ashley Gearhardt and colleagues

  40. 40
    top 2.5%

    Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis

    Hristelina S. Ilieva, Mithila Vullaganti, Justin Y. Kwan

    111 citationsOpen access (CC-BY-NC)doi:10.1136/bmj-2023-075037OpenAlex

    Show abstract

    Although the past two decades have produced exciting discoveries in the genetics and pathology of amyotrophic lateral sclerosis (ALS), progress in developing an effective therapy remains slow. This review summarizes the critical discoveries and outlines the advances in disease characterization, diagnosis, imaging, and biomarkers, along with the current status of approaches to ALS care and treatment. Additional knowledge of the factors driving disease progression and heterogeneity will hopefully soon transform the care for patients with ALS into an individualized, multi-prong approach able to prevent disease progression sufficiently to allow for a dignified life with limited disability.

  41. 41
    top 2.5%

    Adverse pregnancy outcomes and long term risk of ischemic heart disease in mothers: national cohort and co-sibling study

    Casey Crump, Jan Sundquist, Mary Ann McLaughlin, Siobhan M. Dolan, Usha S. Govindarajulu and 2 more

    111 citationsOpen access (CC-BY-NC)doi:10.1136/bmj-2022-072112OpenAlex

    Show abstract

    OBJECTIVE: To examine the associations between five major adverse pregnancy outcomes and long term risks of ischemic heart disease in mothers. DESIGN: National cohort study. SETTING: Sweden. PARTICIPANTS: All 2 195 266 women with a first singleton delivery in Sweden during 1973-2015. MAIN OUTCOME MEASURES: The main outcome measure was incidence of ischemic heart disease from delivery to 2018, identified from nationwide inpatient and outpatient diagnoses. Cox regression was used to calculate hazard ratios for ischemic heart disease associated with preterm delivery, small for gestational age, pre-eclampsia, other hypertensive disorders of pregnancy, and gestational diabetes, adjusting for other adverse pregnancy outcomes and maternal factors. Co-sibling analyses assessed for confounding by shared familial (genetic and environmental) factors. RESULTS: During 53.6 million person years of follow-up, ischemic heart disease was diagnosed in 83 881 (3.8%) women. All five adverse pregnancy outcomes were independently associated with increased risk of ischemic heart disease. In the 10 years…

  42. 42
    top 2.6%

    Advances in the management of pancreatic cancer

    Marco Del Chiaro, Toshitaka Sugawara, Sana D. Karam, Wells A. Messersmith

    110 citationsOpen accessdoi:10.1136/bmj-2022-073995OpenAlex

    Show abstract

    Pancreatic cancer remains among the malignancies with the worst outcomes. Survival has been improving, but at a slower rate than other cancers. Multimodal treatment, including chemotherapy, surgical resection, and radiotherapy, has been under investigation for many years. Because of the anatomical characteristics of the pancreas, more emphasis on treatment selection has been placed on local extension into major vessels. Recently, the development of more effective treatment regimens has opened up new treatment strategies, but urgent research questions have also become apparent. This review outlines the current management of pancreatic cancer, and the recent advances in its treatment. The review discusses future treatment pathways aimed at integrating novel findings of translational and clinical research.

  43. 43
    top 2.7%

    Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study

    Lisa Lundberg, Susannah Leach, Yiyi Xu, Jari Martikainen, Ailiana Santosa and 4 more

    108 citationsOpen access (CC-BY)doi:10.1136/bmj-2023-076990OpenAlex

    Show abstract

    OBJECTIVE: To investigate the effectiveness of primary covid-19 vaccination (first two doses and first booster dose within the recommended schedule) against post-covid-19 condition (PCC). DESIGN: Population based cohort study. SETTING: Swedish Covid-19 Investigation for Future Insights-a Population Epidemiology Approach using Register Linkage (SCIFI-PEARL) project, a register based cohort study in Sweden. PARTICIPANTS: All adults (≥18 years) with covid-19 first registered between 27 December 2020 and 9 February 2022 (n=589 722) in the two largest regions of Sweden. Individuals were followed from a first infection until death, emigration, vaccination, reinfection, a PCC diagnosis (ICD-10 diagnosis code U09.9), or end of follow-up (30 November 2022), whichever came first. Individuals who had received at least one dose of a covid-19 vaccine before infection were considered vaccinated. MAIN OUTCOME MEASURE: The primary outcome was a clinical diagnosis of PCC. Vaccine effectiveness against PCC was estimated using Cox regressions adjusted for age, sex, comorbidities (diabetes and…

  44. 44
    top 2.7%

    Recommendations for the development, implementation, and reporting of control interventions in efficacy and mechanistic trials of physical, psychological, and self-management therapies: the CoPPS Statement

    David Hohenschurz‐Schmidt, Lene Vase, Whitney Scott, Marco Annoni, Oluwafemi K Ajayi and 25 more

    106 citationsOpen accessdoi:10.1136/bmj-2022-072108OpenAlex

    Show abstract

    Control interventions (often called “sham,” “placebo,” or “attention controls”) are essential for studying the efficacy or mechanism of physical, psychological, and self-management interventions in clinical trials. This article presents core recommendations for designing, conducting, and reporting control interventions to establish a quality standard in non-pharmacological intervention research. A framework of additional considerations supports researchers’ decision making in this context. We also provide a reporting checklist for control interventions to enhance research transparency, usefulness, and rigour.

  45. 45
    top 2.8%

    Molnupiravir and risk of post-acute sequelae of covid-19: cohort study

    Yan Xie, Taeyoung Choi, Ziyad Al‐Aly

    106 citationsOpen access (CC-BY-NC)doi:10.1136/bmj-2022-074572OpenAlex

    Show abstract

    OBJECTIVE: To examine whether treatment with the antiviral agent molnupiravir during the first five days of SARS-CoV-2 infection is associated with reduced risk of post-acute adverse health outcomes. DESIGN: Cohort study. SETTING: US Department of Veterans Affairs. PARTICIPANTS: 229 286 participants who tested positive for SARS-CoV-2 between 5 January 2022 and 15 January 2023, had at least one risk factor for progression to severe covid-19, and survived the first 30 days after testing positive were enrolled. 11 472 participants received a prescription for molnupiravir within five days of the positive test result and 217 814 received no covid-19 antiviral or antibody treatment (no treatment group). MAIN OUTCOME MEASURES: Risks of post-acute sequelae of SARS-CoV-2 (PASC, defined based on a prespecified set of 13 post-acute sequelae), post-acute death, post-acute hospital admission, and each individual post-acute sequela between the molnupiravir group and no treatment group were examined after application of inverse probability weighting to balance the treatment and no treatment…

  46. 46
    top 2.8%

    Menopausal hormone therapy and dementia: nationwide, nested case-control study

    Nelsan Pourhadi, Lina Steinrud Mørch, Ellen Holm, Christian Tobias Torp-Pedersen, Amani Meaidi

    100 citationsOpen access (CC-BY-NC)doi:10.1136/bmj-2022-072770OpenAlex

    Show abstract

    OBJECTIVES: To assess the association between use of menopausal hormone therapy and development of dementia according to type of hormone treatment, duration of use, and age at usage. DESIGN: Nationwide, nested case-control study. SETTING: Denmark through national registries. PARTICIPANTS: 5589 incident cases of dementia and 55 890 age matched controls were identified between 2000 and 2018 from a population of all Danish women aged 50-60 years in 2000 with no history of dementia or contraindications for use of menopausal hormone therapy. MAIN OUTCOME MEASURES: Adjusted hazard ratios with 95% confidence intervals for all cause dementia defined by a first time diagnosis or first time use of dementia specific medication. RESULTS: Compared with people who had never used treatment, people who had received oestrogen-progestogen therapy had an increased rate of all cause dementia (hazard ratio 1.24 (95% confidence interval 1.17 to 1.33)). Increasing durations of use yielded higher hazard ratios, ranging from 1.21 (1.09 to 1.35) for one year or less of use to 1.74 (1.45 to 2.10) for more…

  47. 47
    top 2.9%

    Efficacy, safety, and tolerability of antidepressants for pain in adults: overview of systematic reviews

    Giovanni Esteves Ferreira, Christina Abdel Shaheed, Martin R Underwood, Nanna Brix Finnerup, Richard Osborne Day and 4 more

    100 citationsOpen access (CC-BY-NC)doi:10.1136/bmj-2022-072415OpenAlex

    Show abstract

    OBJECTIVE: To provide a comprehensive overview of the efficacy, safety, and tolerability of antidepressants for pain according to condition. DESIGN: Overview of systematic reviews. DATA SOURCES: PubMed, Embase, PsycINFO, and the Cochrane Central Register of Controlled Trials from inception to 20 June 2022. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Systematic reviews comparing any antidepressant with placebo for any pain condition in adults. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently extracted data. The main outcome measure was pain; for headache disorders it was frequency of headaches. Continuous pain outcomes were converted into a scale of 0 (no pain) to 100 (worst pain) and were presented as mean differences (95% confidence intervals). Dichotomous outcomes were presented as risk ratios (95% confidence intervals). Data were extracted from the time point closest to the end of treatment. When end of treatment was too variable across trials in a review, data were extracted from the outcome or time point with the largest number of trials and participants. Secondary…

  48. 48
    top 3%

    Development and internal-external validation of statistical and machine learning models for breast cancer prognostication: cohort study

    Ash Kieran Clift, David John Dodwell, Simon Lord, Stavros Petrou, Michael Brady and 2 more

    97 citationsOpen access (CC-BY)doi:10.1136/bmj-2022-073800OpenAlex

    Show abstract

    OBJECTIVE: To develop a clinically useful model that estimates the 10 year risk of breast cancer related mortality in women (self-reported female sex) with breast cancer of any stage, comparing results from regression and machine learning approaches. DESIGN: Population based cohort study. SETTING: QResearch primary care database in England, with individual level linkage to the national cancer registry, Hospital Episodes Statistics, and national mortality registers. PARTICIPANTS: 141 765 women aged 20 years and older with a diagnosis of invasive breast cancer between 1 January 2000 and 31 December 2020. MAIN OUTCOME MEASURES: Four model building strategies comprising two regression (Cox proportional hazards and competing risks regression) and two machine learning (XGBoost and an artificial neural network) approaches. Internal-external cross validation was used for model evaluation. Random effects meta-analysis that pooled estimates of discrimination and calibration metrics, calibration plots, and decision curve analysis were used to assess model performance, transportability, and…

  49. 49
    top 3%

    Beverage consumption and mortality among adults with type 2 diabetes: prospective cohort study

    Le Ma, Yang Hu, Derrick Johnston Alperet, Gang Liu, Vasanti Malik and 4 more

    96 citationsOpen access (CC-BY)doi:10.1136/bmj-2022-073406OpenAlex

    Show abstract

    OBJECTIVE: To investigate the intake of specific types of beverages in relation to mortality and cardiovascular disease (CVD) outcomes among adults with type 2 diabetes. DESIGN: Prospective cohort study. SETTING: Health professionals in the United States. PARTICIPANTS: 15 486 men and women with a diagnosis of type 2 diabetes at baseline and during follow-up (Nurses' Health Study: 1980-2018; and Health Professionals Follow-Up Study: 1986-2018). Beverage consumption was assessed using a validated food frequency questionnaire and updated every two to four years. MAIN OUTCOME MEASURES: The main outcome was all cause mortality. Secondary outcomes were CVD incidence and mortality. RESULTS: During an average of 18.5 years of follow-up, 3447 (22.3%) participants with incident CVD and 7638 (49.3%) deaths were documented. After multivariable adjustment, when comparing the categories of lowest intake of beverages with the highest intake, the pooled hazard ratios for all cause mortality were 1.20 (95% confidence interval 1.04 to 1.37) for sugar sweetened beverages (SSBs), 0.96 (0.86 to 1.07)…

  50. 50
    top 3.1%

    Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial

    Fei Ma, Min Yan, Wěi Li, Quchang Ouyang, Zhongsheng Tong and 25 more

    94 citationsOpen access (CC-BY-NC)doi:10.1136/bmj-2023-076065OpenAlex

    Show abstract

    OBJECTIVE: To assess the efficacy and safety of pyrotinib (an irreversible pan-HER (human epidermal growth factor receptor) inhibitor), trastuzumab, and docetaxel compared with placebo, trastuzumab, and docetaxel for untreated HER2 positive metastatic breast cancer. DESIGN: Randomised, double blind, placebo controlled, multicentre, phase 3 trial. SETTING: 40 centres in China between 6 May 2019 and 17 January 2022. PARTICIPANTS: 590 female patients (median age 52 (interquartile range 46-58) years) with untreated HER2 positive metastatic breast cancer. INTERVENTIONS: ) on day 1 of each 21 day cycle. Randomisation was stratified by treatment history of trastuzumab in the (neo)adjuvant setting and hormone receptor status. Patients, investigators, and the sponsor's study team were masked to treatment assignment. MAIN OUTCOME MEASURES: The primary endpoint was progression-free survival as assessed by the investigator. RESULTS: Of the 590 randomised patients, 297 received pyrotinib, trastuzumab, and docetaxel treatment (pyrotinib group), and 293 received placebo, trastuzumab, and docetaxel…

How to read this list

The cohort is every article, review and book chapter OpenAlex attributes to BMJ with publication year 2023, excluding retracted works and paratext such as editorials and errata. The top 50 by citation count are listed; the percentile is the rank divided by the cohort size. 50 of the 50 entries have an abstract in OpenAlex. Counts were read on 29 October 2026 and will not be updated on this page, so a quoted rank stays verifiable. Full rules on the methodology page.

Other journals, same idea

Work with these 25 papers in Kahubi

  • The papers land in your library with their DOIs
  • Ask anything across all of them, with citations
  • Draft a literature review from the same sources

Free plan, no card. Your files stay private unless you share them.

Reading several of these?

Kahubi reads papers with you, keeps every citation traceable and drafts with sources you can check. Free plan, no card.